Arcataur Capital Management LLC Buys 37 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Arcataur Capital Management LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,038 shares of the biopharmaceutical company’s stock after purchasing an additional 37 shares during the quarter. Arcataur Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $545,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. Bingham Private Wealth LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $224,000. Valeo Financial Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 50.4% during the 2nd quarter. Valeo Financial Advisors LLC now owns 1,787 shares of the biopharmaceutical company’s stock worth $938,000 after acquiring an additional 599 shares during the period. Keudell Morrison Wealth Management lifted its stake in Regeneron Pharmaceuticals by 18.8% in the 2nd quarter. Keudell Morrison Wealth Management now owns 695 shares of the biopharmaceutical company’s stock worth $365,000 after purchasing an additional 110 shares in the last quarter. Marietta Wealth Management LLC boosted its holdings in Regeneron Pharmaceuticals by 6.2% in the 2nd quarter. Marietta Wealth Management LLC now owns 11,451 shares of the biopharmaceutical company’s stock valued at $6,012,000 after purchasing an additional 673 shares during the period. Finally, Checchi Capital Advisers LLC boosted its holdings in Regeneron Pharmaceuticals by 7.3% in the 2nd quarter. Checchi Capital Advisers LLC now owns 732 shares of the biopharmaceutical company’s stock valued at $384,000 after purchasing an additional 50 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $583.24 on Wednesday. The firm has a market capitalization of $61.82 billion, a PE ratio of 14.70, a price-to-earnings-growth ratio of 1.87 and a beta of 0.31. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,024.36. The business’s 50-day moving average price is $573.16 and its 200-day moving average price is $566.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the prior year, the firm earned $11.56 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 3.6% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Argus cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, June 30th. Jefferies Financial Group boosted their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research report on Wednesday, August 27th. Morgan Stanley reaffirmed an “overweight” rating and issued a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Canaccord Genuity Group reiterated a “buy” rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Finally, UBS Group restated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.